Carl Zeiss Meditec (ISIN: DE0005313704) has grown revenues to around EUR 667 million in the first six months of fiscal year 2018/19, based on preliminary data. This corresponds to a growth rate of approx. 9% against the previous year’s value of EUR 613.7 million. Adjusted for currency effects, the growth rate was around 7%.
Carl Zeiss Meditec now further defines its expectations for the full year 2018/19: Revenue is expected to reach between EUR 1,350 million and EUR 1,420 million (previous year: EUR 1,280.9 million).
Earnings before interest and taxes (EBIT) are expected to rise significantly in the first half of 2018/19 to a level of around EUR 110 million (previous year: EUR 88.2 million). EBIT margin (EBIT as a % of revenue) will amount to around 16.5% in the first half of 2018/19 (previous year: 14.4%). The increase was supported by a positive trend in product mix with a high share of recurring revenue, in particular.
In light of these developments, Carl Zeiss Meditec raises the expectation for full year EBIT margin. EBIT margin is now expected to reach a corridor of 15.0% - 17.5% (previously: 14.0% - 16.0%). EBIT margin had amounted to 15.4% in the previous year 2017/18.
The six months 2018/19 financial report will be published on May 6, 2019.
Contact for investors and press
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,050 employees worldwide, the Group generated revenue of €1,280.9m in fiscal year 2017/18 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at: www.zeiss.com/med